MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for patients suffering from serious diseases, with a focus on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.
Please click on the link below to visit our virtual booth
Press Releases